#United States #Tampa #AML #TuHURA #TBS-2025

TuHURA Biosciences Takes a Major Step Forward with TBS-2025

In a significant announcement, TuHURA Biosciences, Inc., a company focused on developing innovative immunotherapies, revealed that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for TBS-2025, an antibody designed to inhibit VISTA for treating specific subtypes of Acute Myeloid Leukemia (AML) and other hematological cancers. This vital move comes after extensive feedback from the FDA regarding their development strategy, which includes both monotherapy and potential combination therapies.

The IND application reflects TuHURA's commitment to addressing the urgent medical needs of patients with AML, particularly those with mutations such as NPM1, which affects around 60-70% of AML cases. With no effective treatments currently approved for subsets of AML, the company’s efforts represent a beacon of hope for patients grappling with these severe conditions. According to Dr. James Bianco, TuHURA's President and CEO, this initiative positions the firm at the forefront of cancer immunotherapy for hematologic malignancies. He emphasized the company’s pioneering role in exploring VISTA inhibition to enhance patient outcomes in hematologic cancers.

The company aims to initiate the Phase 1b/2 trial in the latter part of 2026, which will assess the safety and efficacy of TBS-2025 in patients who have experienced relapsed or refractory AML. The trial design has been refined thanks to valuable guidance from the FDA, making it possible to combine the two phases into a more streamlined study, potentially accelerating timelines significantly.

Dr. Craig Tendler, Chief Medical Officer of TuHURA, noted that the Phase 1b segment will specifically explore dosing levels for these patients. If the necessary biological effects and safety thresholds are confirmed, TuHURA plans to collaborate closely with the FDA to expand the study, aiming for possible accelerated approval similar to that granted to menin inhibitors for comparable patient populations.

In particular, TBS-2025 is being tested for its potential to improve both the rates and duration of complete responses when used in conjunction with menin inhibitors in patients with mutated NPM1 AML. With its unique mechanism of action, TBS-2025 targets the VISTA checkpoint, which plays a crucial role in cancer's ability to evade the immune system—offering a new pathway for treatment when traditional options have failed.

Previously, TBS-2025 was evaluated in a Phase 1 clinical trial as either a standalone treatment or in combination with pembrolizumab for various solid tumors. Results indicated a favorable safety profile, even at high doses, reinforcing the rationale for its investigation in AML.

TuHURA's broader ambition includes advancing its innate immune agonist, IFx-2.0, designed to combat inherent resistance to current checkpoint inhibition therapies, with ongoing Phase 3 trial outcomes anticipated for its efficacy in treating advanced Merkel Cell Carcinoma.

As TuHURA looks ahead, its innovative approach aims to address critical unmet needs in oncology, with TBS-2025 emerging as a key player in redefining treatment strategies. With robust scientific backing and a strong regulatory pathway in place, TuHURA Biosciences is poised to potentially change the landscape for patients with hematologic cancers. For additional information about TuHURA and its therapeutic innovations, visit their website at www.tuhurabio.com.

With these developments, TuHURA not only embodies progress in cancer treatment but also stands as a testament to how innovative research efforts can pave the way for new solutions in the fight against cancer.